The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (¹⁷⁷Lu)-PSMA-617.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Prostate Pub Date : 2025-01-01 Epub Date: 2024-09-29 DOI:10.1002/pros.24804

Satı Coskun Yazgan, Emre Yekeduz, Mine Araz, Hatice Bolek, N Ozlem Kucuk, Yuksel Urun

{"title":"The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617.","authors":"Satı Coskun Yazgan, Emre Yekeduz, Mine Araz, Hatice Bolek, N Ozlem Kucuk, Yuksel Urun","doi":"10.1002/pros.24804","DOIUrl":null,"url":null,"abstract":"Background: Pan-immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 (177Lu)-PSMA-617.Methods: The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis.Results: A total of 43 patients with mCRPC treated with (177Lu)-PSMA-617 were included. The median OS was longer in the low PIV group (15.1 months [95% confidence interval [CI] 10.6-19.5]) than in the high PIV group (4.2 months [95% CI 1.7-6.6]) (p < 0.001). In multivariable analysis, high PIV (hazard ratio [HR]: 4.3, 95% CI 1.194-15.93, p = 0.026) and high Eastern Cooperative Oncology Group performance score (HR: 7.05, 95% CI 1.48-33.46, p = 0.014) were associated with shorter OS.Conclusion: This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with (177Lu)-PSMA-617.","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"90-96"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24804","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pan-immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 (¹⁷⁷Lu)-PSMA-617.

Methods: The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis.

Results: A total of 43 patients with mCRPC treated with (¹⁷⁷Lu)-PSMA-617 were included. The median OS was longer in the low PIV group (15.1 months [95% confidence interval [CI] 10.6-19.5]) than in the high PIV group (4.2 months [95% CI 1.7-6.6]) (p < 0.001). In multivariable analysis, high PIV (hazard ratio [HR]: 4.3, 95% CI 1.194-15.93, p = 0.026) and high Eastern Cooperative Oncology Group performance score (HR: 7.05, 95% CI 1.48-33.46, p = 0.014) were associated with shorter OS.

Conclusion: This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with (¹⁷⁷Lu)-PSMA-617.

查看原文本刊更多论文

接受镥-177 (177Lu)-PSMA-617 治疗的转移性去势抵抗性前列腺癌患者泛免疫炎症值的预后作用。

背景：泛免疫炎症值（PIV）是一种新定义的生物标志物，它包括全血细胞计数（CBC）中作为全身炎症指标的全细胞成分，易于获得，并有可能同时反映机体的免疫反应和全身炎症状态。本研究评估了接受镥-177（177Lu）-PSMA-617 治疗的转移性去势抵抗性前列腺癌（mCRPC）患者治疗前的 PIV 对总生存期（OS）的预后影响：PIV基于治疗开始前1个月内最早获得的全血细胞计数。根据治疗前PIV的中位数将患者分为低PIV组和高PIV组，并通过多变量分析评估OS与PIV组之间的关系：共纳入43例接受(177Lu)-PSMA-617治疗的mCRPC患者。低PIV组的中位OS（15.1个月[95% 置信区间[CI] 10.6-19.5]）长于高PIV组（4.2个月[95% CI 1.7-6.6]）：本研究表明，对于接受(177Lu)-PSMA-617治疗的mCRPC患者来说，治疗前PIV可能是一个预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate 医学-泌尿学与肾脏学

CiteScore

5.10

自引率

3.60%

发文量

180

审稿时长

1.5 months

期刊介绍： The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.